Rilmenidine treatment in patients with mild to moderate arterial hypertension and metabolic syndrome

Rilmenidine treatment in patients with mild to moderate arterial hypertension and metabolic syndrome

Efficacy, tolerability and cardioprotective properties of rilmenidine were examined in patients with mild to moderate arterial hypertension (AH). The trial involved 51 hypertensive subjects, mean age 57,7+2,5 years. After wash-out period, rilmenidine was administered in the daily dose of 1-2 mg. At...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	S. S. Yakushin, N. I. Ivankova, N. S. Sazonova, N. V. Vilesova, G. O. Ivanova
Fformat:	Erthygl
Iaith:	Russian
Cyhoeddwyd:	«FIRMA «SILICEA» LLC 2004-12-01
Cyfres:	Российский кардиологический журнал
Pynciau:	arterial hypertension metabolic syndrome cardioprotective effects rilmenidine
Mynediad Ar-lein:	https://russjcardiol.elpub.ru/jour/article/view/2326

Eitemau Tebyg

EFFECT OF ANTIHYPERTENSIVE THERAPY WITH RILMENIDINE ON COGNITIVE FUNCTION IN ELDERLY HYPERTENSIVE PATIENTS
gan: S. V. Nedogoda, et al.
Cyhoeddwyd: (2016-01-01)

ASSESSMENT OF RILMENIDINE EFFICIENCY IN PATIENTS WITH ARTERIAL HYPERTENSION WITH DETERIORATION OF DAILY PROFILE OF BLOOD PRESSURE
gan: P. P. Tikhonov, et al.
Cyhoeddwyd: (2015-12-01)

Perspectives of decreasing individual cardiovascular risk in high- and very high risk patients with arterial hypertension, treated with rilmenidine
gan: S. V. Nedogoda, et al.
Cyhoeddwyd: (2005-06-01)

Workplace arterial hypertension: potential of rilmenidine-based combination therapy
gan: S. I. Drozdetsky, et al.
Cyhoeddwyd: (1970-01-01)

Rilmenidine treatment in hypertensive patients with cerebrovascular transient ischemic attacks
gan: A. P. Kondrakhin, et al.
Cyhoeddwyd: (2005-10-01)

Rilmenidine therapy potential in pharmaceutical correction of endothelial dysfunction among women with arterial hypertension, Type 2 diabetes mellitus, and visceral obesity
gan: E. V. Eliseeva, et al.
Cyhoeddwyd: (1970-01-01)

THE WAYS OF SYMPATHETIC SYSTEM OVERACTIVITY BLOCKING: RILMENIDINE VERSUS ATENOLOL
gan: Y. R. Kasherininov, et al.
Cyhoeddwyd: (2016-01-01)

Autophagy and anti-inflammation ameliorate diabetic neuropathy with Rilmenidine
gan: Mehmet Burak Yalçın, et al.
Cyhoeddwyd: (2023-12-01)

Rilmenidine Protects Against Joint Damage in MIA-induced Model of Osteoarthritis in Rats
gan: Osman Kukula, et al.
Cyhoeddwyd: (2024-02-01)

Stimulation of mTOR-independent autophagy and mitophagy by rilmenidine exacerbates the phenotype of transgenic TDP-43 mice
gan: Nirma D. Perera, et al.
Cyhoeddwyd: (2021-07-01)

Main results of the Russian trial «ALTAIR»
gan: E. V. Shlyakhto, et al.
Cyhoeddwyd: (2006-02-01)

ARTERIAL HYPERTENSION IN YOUNG PEOPLE: EFFICACY OF SYMPATHOLYTIC THERAPY
gan: N. N. Nikitina, et al.
Cyhoeddwyd: (2015-12-01)

Comparison in conscious rabbits of the baroreceptor-heart rate reflex effects of chronic treatment with rilmenidine, moxonidine, and clonidine
gan: Monique L Parkin, et al.
Cyhoeddwyd: (2016-11-01)

Effects of centrally acting antihypertensive drugs on the microcirculation of spontaneously hypertensive rats
gan: V. Estato, et al.
Cyhoeddwyd: (2004-10-01)

PHARMACEUTICAL CORRECTION OF VASCULAR DISTURBANCES IN PATIENTS WITH ARTERIAL HYPERTENSION
gan: L. A. Khaisheva, et al.
Cyhoeddwyd: (2010-10-01)

Combined treatment of arterial hypertension: focus on calcium antagonist and ACE inhibitor combination
gan: V. I. Makolkin
Cyhoeddwyd: (2008-12-01)

Not first‐line antihypertensive agents, but still effective—The efficacy and safety of imidazoline receptor agonists: A network meta‐analysis
gan: András Érszegi, et al.
Cyhoeddwyd: (2024-06-01)

Cerebral blood flow and blood rheology in hypertensive patients during rilmenidine treatment
gan: L. I. Markova, et al.
Cyhoeddwyd: (2004-06-01)

BISOPROLOL AND METFORMIN IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME
gan: V. A. Nevzorova, et al.
Cyhoeddwyd: (2015-12-01)

Prevalence of metabolic syndrome and its components in patients with arterial hypertension and obesity
gan: I. E. Chazova, et al.
Cyhoeddwyd: (2005-12-01)

Valsartan effects on platelet activity in patients with arterial hypertension and metabolic syndrom
gan: I. N. Medvedev, et al.
Cyhoeddwyd: (2007-06-01)

Reduced platelet aggregation in losartan-treated patients with arterial hypertension and metabolic syndrome
gan: I. N. Medvedev, et al.
Cyhoeddwyd: (2008-10-01)

Eprosartan effects on intravascular platelet activity in patients with arterial hypertension and metabolic syndrome
gan: I. N. Medvedev, et al.
Cyhoeddwyd: (2008-02-01)

Intravascular platelet activity correction by fosinopril in arterial hypertension patients with metabolic syndrome
gan: I. N. Medvedev, et al.
Cyhoeddwyd: (2006-10-01)

Microcirculatory function in patients with arterial hypertension, metabolic syndrome and diabetes mellitus
gan: A. P. Vasilyev, et al.
Cyhoeddwyd: (2008-10-01)

Some hormonal systems in males with arterial hypertension and metabolic syndrome
gan: A. N. Britov, et al.
Cyhoeddwyd: (2006-06-01)

Metabolic syndrome in patients with arterial hypertension living in the Far North (on the example of the Khanty-Mansi Autonomous Okrug — Yugra)
gan: E. G. Ivanova, et al.
Cyhoeddwyd: (2023-04-01)

CORRECTION OF AGGREGATIVE FUNCTION OF THE TROMBOCYTES IN ARTERIAL HYPERTENSION PATIENTS WITH METABOLIC SYNDROM UNDER THE INFLUENCE OF SIMVASTATINE
gan: N. J. Gromnazky, et al.
Cyhoeddwyd: (2003-12-01)

The comorbid patients with arterial hypertension, chronic heart failure and chronic kidney disease: the role of fosinoprile
gan: G. N. Gorokhovskaya, et al.
Cyhoeddwyd: (2018-04-01)

Arterial hypertension and metabolic syndrome: specifics of antihypertensive therapy
gan: L. I. Abasova, et al.
Cyhoeddwyd: (2011-08-01)

Features of the clinical course of arterial hypertension in alien residents of Western Siberia with the establishment of patterns of metabolic changes
gan: E. G. Ivanova, et al.
Cyhoeddwyd: (2022-07-01)

Spirapril effects on heart remodeling in patients with mild to moderate arterial hypertension
gan: M. M. Beraya, et al.
Cyhoeddwyd: (2007-02-01)

Pathogenesis of arterial hypertension within the metabolic syndrome
gan: A S Ryazanov, et al.
Cyhoeddwyd: (2003-03-01)

Antihypertensive spirapril effectiveness in patients with mild to moderate arterial hypertension
gan: M. M. Beraya, et al.
Cyhoeddwyd: (1970-01-01)

Imidazoline receptor agonist moxonidine and arterial hypertension treatment in women with menopausal metabolic syndrome
gan: E. V. Tishina, et al.
Cyhoeddwyd: (2011-06-01)

Moxonidine for arterial hypertension treatment in menopausal women with metabolic syndrome
gan: V. V. Trusov, et al.
Cyhoeddwyd: (2007-08-01)

AFFECTIVE DISORDERS IN MEN WITH ARTERIAL HYPERTENSION IN COMBINATION WITH METABOLIC SYNDROME
gan: Roman A. Yaskevich, et al.
Cyhoeddwyd: (2022-08-01)

AFFECTIVE DISORDERS IN WOMEN WITH ARTERIAL HYPERTENSION IN COMBINATION WITH METABOLIC SYNDROME
gan: Roman A. Yaskevich, et al.
Cyhoeddwyd: (2022-06-01)

SHIFTWORK AS ONE OF RISK FACTORS OF ARTERIAL HYPERTENSION AND METABOLIC DISORDERS
gan: I. S. Dzherieva, et al.
Cyhoeddwyd: (2015-12-01)

The efficacy of available supplements and medical drugs in longevity medicine - a review
gan: Michał Łata, et al.
Cyhoeddwyd: (2025-01-01)